Lilly ' s SURPASS-2 Results Published in The New England Journal of Medicine Show Tirzepatide Achieved Superior A1C and Body Weight Reductions Compared to Injectable Semaglutide in Adults with Type 2 diabetes

INDIANAPOLIS, June 25, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company ' s (NYSE: LLY) SURPASS-2 clinical...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials